On August 13, 2025, Salesforce signed a definitive agreement to acquire Bluebirds, an industry leading agentic Artificial Intelligence (AI) platform that focuses on developing sales prospects before a representative would take over the lead. Below, we unpack the Salesforce-Bluebirds acquisition and what it means for agentic AI in the life sciences moving forward.

What is Agentic AI? 

Agentic AI refers to an AI solution comprised of agents: autonomous AI that track data and actions to make proactive decisions and assist in dedicated tasks without needing constant human input. 

Who is Bluebirds? 

Bluebirds’s specific capabilities center on warm lead retargeting. Specifically, they have built a core secret sauce around contacts that have fallen out of view due to switching jobs – hence the namesake “Bluebirds.” This is a direct addressing of a likely gap Salesforce sees in terms of incapabilities between themselves and Veeva for affiliations.  

How does Bluebirds fuel the competition between Salesforce and Veeva? 

One of Veeva’s core offering is Veeva OpenData – the pharma standard for master data around HCP/HCO affiliations. Once most companies pair this with Veeva Open networks, they have their best and most complete picture of targets and their affiliations. Bluebirds will not be able to replicate OpenData – given the amount of history in that tool, but it can start to chip away at Veeva’s institutional knowledge by instead using powerful models to infer this knowledge. Salesforce is looking for different ways to skip past the manpower of managing cross-company HCO/HCP identification to get to a similar end result. 

What does the Bluebirds acquisition mean for Salesforce’s AI strategy? 

Following its acquisitions of Convergence.ai and Informatica, the Bluebirds acquisition aligns with Salesforce’s larger strategy of being the industry’s AI leader. Its effects could help drive business for life sciences companies engaging with healthcare providers (HCPs) through Salesforce’s Life Science Customer Relationship Management (CRM).  

As Salesforce continues to bolster its CRM offering for pharma and life sciences companies after the split from Veeva, the company is leaning into its AI capabilities as the go to value-add for HCP engagement. The acquisition of Bluebirds fits particularly well into this vision, specifically within Salesforces Agentforce. With the context of the Bluebirds acquisition, the life sciences Agentforce capabilities will likely be centered around HCP engagement. Salesforce leverages their agent AI capabilities to tailor outreach based on things like prescribing history, specialty, event attendance, and even call notes from previous meetings. With all of this data, AI agents could even be used coach sales reps on sales or pitches at different stages of opportunities.  

The secret ingredient in employing agentic AI in sales is the harmonization of automated time-consuming pre-sale tasks and nuanced human interaction. AI agents can handle pre-sales/prospecting aspects in three main areas: 

1. Call planning/HCP targeting (identifying high value, high success rate HCPs utilizing data on sales trends and prescribing behavior) 
2. Post-meeting summaries (automatically transcribing the meeting and generating action items) 
3. Sales prep (developing insights, next best actions, and tailored coaching plans suited for the individual opportunity).  

At this point, a human sales rep can take on the sale well outfitted with insights and perspectives to make their pitch more impactful and robust.  

This is where the Bluebirds acquisition fits in; its leading capabilities in top-of-funnel prospecting and expertise in sales data-driven agentic AI continue to put Salesforce Life Sciences Cloud at the leading edge of AI capabilities. Bluebirds’ agent AI capabilities should augment Agentforce, reducing the time needed by sales reps to find and develop opportunities, empowering sales reps to be more effective and more impactful.  

The acquisition [of Bluebirds] is expected to close in the third quarter of Salesforce’s fiscal year 2026, subject to satisfaction of customary closing conditions.